NCT06990867RecruitingPhase 2/3
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Optimizing Reperfusion to Improve Outcomes and Neurologic Function (ORION): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of JX10 in Acute Ischemic Stroke With Late Presentations
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
The goal of this study is to evaluate the safety and efficacy of JX10 versus placebo in participants with Acute Ischemic Stroke (AIS) who present for care within 4.5 to 24 hours. The main question the study aims to answer are: 1. JX10 improves functional outcomes as measured by the modified Rankin Scale score when compared with placebo following AIS. 2. Risk of symptomatic intracranial hemorrhage of JX10 in participants with AIS. During Part 1, participants will be randomized to JX 10 (1mg/kg, 3 mg/kg) or placebo. During Part 2, participants will receive JX10 (optimal dose chosen from Part 1) or placebo.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 740 (estimated)
- First submitted
- 22 May 2025
- Start date
- May 2025
- Primary completion date
- Oct 2029
- Lead sponsor
- Corxel Pharmaceuticals
- Diseases
- Stroke
- NCT number
- NCT06990867
What you commit to
- Study type: Interventional · Phase 2/3
- Planned participants: 740
- From May 2025 to the primary completion date, Oct 2029
- 101 sites in 21 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major trauma, surgery, or invasive procedures.
Other illness
- Radiographic findings pre-randomization of any of the following:
- Large core infarction, or
- Occlusion in more than 1 vascular territory, or
- Significant mass effect or clinically significant cerebral edema, or
- Evidence of acute intracranial or extracranial hemorrhage, intracranial tumor (except small meningioma), neoplasm, or arteriovenous malformation), or
- Clinical history, past imaging, or clinical judgement suggests that the intracranial occlusion is chronic.
- Medical history or active clinically significant bleeding, lesions, or conditions (at the investigator's judgement) considered to be of significant risk for major bleeding.
- Severe, uncontrolled hypertension (systolic blood pressure ≥ 185 mmHg or diastolic blood pressure ≥ 110 mmHg) that cannot be controlled with antihypertensive therapy.
- Pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations of this study.
Lab values
- Known bleeding diathesis (hereditary or acquired) or any significant coagulopathy. Specifically, platelet count \< 100,000/μL, international normalized ratio \> 1.7, aPTT \> 40 seconds, or prothrombin time \> 15 seconds.
- Pre-treatment blood glucose \> 400 mg/dL (22.20 mmol/L) or Pre-treatment blood glucose \< 50 mg/dL (2.78 mmol/L) unless it is corrected prior to study treatment administration. Participants with subsequently normalized blood glucose levels may be considered for inclusion, per Investigator judgement.
Who the study is looking for
- Age ≥ 18 and ≤ 90 years old.
- Acute ischemic stroke with compatible clinical presentation and symptomatic high grade or complete occlusion of the intracranial internal carotid, M1, M2 or distal branches of the middle cerebral artery (MCA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA).
- Radiographic evidence of salvageable tissue.
- Pre-treatment score of NIHSS ≥ 5.
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (101)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.